AR126670A1 - COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS - Google Patents

COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS

Info

Publication number
AR126670A1
AR126670A1 ARP220102053A ARP220102053A AR126670A1 AR 126670 A1 AR126670 A1 AR 126670A1 AR P220102053 A ARP220102053 A AR P220102053A AR P220102053 A ARP220102053 A AR P220102053A AR 126670 A1 AR126670 A1 AR 126670A1
Authority
AR
Argentina
Prior art keywords
nav
kits
compositions
compounds
treatment methods
Prior art date
Application number
ARP220102053A
Other languages
English (en)
Inventor
Gabriela Barreiro
De Santana Danilo Pereira
Gamba Luis Eduardo Reina
Fraga Carlos Alberto Manssour
Lacerda Barreiro Eliezer Jesus De
Lima Ldia Moreira
Original Assignee
Eurofarma Laboratorios S A
Univ Federal Do Rio De Janeiro Ufrj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurofarma Laboratorios S A, Univ Federal Do Rio De Janeiro Ufrj filed Critical Eurofarma Laboratorios S A
Publication of AR126670A1 publication Critical patent/AR126670A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La presente invención se refiere a compuestos N-Acilidrazónicos inhibidores de Nav 1.7 y/o Nav 1.8. Más específicamente, la presente invención relata compuestos N-acilidrazónicos que comprenden la fórmula (1), en que los substitutos R¹ a R⁴ son seleccionados independientemente de los grupos definidos en el informe descriptivo, así como sus procesos de obtención, composiciones comprendiendo por lo menos uno de estos compuestos, usos, métodos de tratamiento para tratar o prevenir patologías relacionadas al dolor y kits. La presente invención se encuentra en los campos de la química medicinal, síntesis orgánica, así como en el tratamiento de enfermedades relacionadas con el dolor.
ARP220102053A 2021-08-02 2022-08-01 COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS AR126670A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163228516P 2021-08-02 2021-08-02

Publications (1)

Publication Number Publication Date
AR126670A1 true AR126670A1 (es) 2023-11-01

Family

ID=85153920

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102053A AR126670A1 (es) 2021-08-02 2022-08-01 COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS

Country Status (4)

Country Link
AR (1) AR126670A1 (es)
CA (1) CA3227736A1 (es)
IL (1) IL310571A (es)
WO (1) WO2023010192A1 (es)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001139566A (ja) * 1999-11-16 2001-05-22 Nippon Nohyaku Co Ltd 有害生物防除剤及びその使用方法
EP1549143A2 (en) * 2002-09-10 2005-07-06 Microbiotix, Inc. Antibacterial pyrazole carboxylic acid hydrazides
CN1842272A (zh) * 2003-05-27 2006-10-04 巴斯福股份公司 用于防治有害昆虫和蜘蛛的腙衍生物
MY148488A (en) * 2004-02-18 2013-04-30 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
CN100355748C (zh) * 2004-09-20 2007-12-19 中国人民解放军军事医学科学院毒物药物研究所 芳酰肼类化合物及其用于制备免疫抑制剂的用途
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
CN101668732A (zh) * 2007-04-02 2010-03-10 同一世界健康研究院 Cftr抑制剂化合物及其用途
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
WO2013123071A1 (en) * 2012-02-13 2013-08-22 Cleave Biosciences, Inc. Methods and compositions for jamm protease inhibition
NZ710111A (en) 2013-01-31 2020-08-28 Vertex Pharma Quinoline and quinoxaline amides as modulators of sodium channels
AR094667A1 (es) 2013-01-31 2015-08-19 Vertex Pharma Piridonamidas como moduladores de canales de sodio
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
CN105473554B (zh) 2013-07-10 2019-08-13 沃泰克斯药物股份有限公司 作为离子通道调节剂的稠合的哌啶酰胺类
TWI668226B (zh) 2013-12-13 2019-08-11 美商維泰克斯製藥公司 作為納通道調節劑之吡啶酮醯胺之前藥
JP2017001991A (ja) 2015-06-11 2017-01-05 大日本住友製薬株式会社 新規ベンズオキサゾロン化合物
JP2019514879A (ja) 2016-04-20 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アシルスルホンアミドＮａＶ１．７阻害剤
WO2017184999A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
BR112019024016A2 (pt) 2017-05-16 2020-06-09 Vertex Pharma amidas de piridona deuteradas e profármacos das mesmas como moduladores de canais de sódio
PT3487839T (pt) 2017-06-20 2021-02-11 Raqualia Pharma Inc Derivados de amida como bloqueadores de nav1.7 e nav1.8
MA49566A (fr) 2017-07-11 2020-05-20 Vertex Pharma Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
CN108774179B (zh) * 2018-05-29 2020-01-21 青岛清原化合物有限公司 一种取代的嘧啶-4-甲酸衍生物及其除草组合物和用途
US20210355103A1 (en) * 2018-07-25 2021-11-18 City Of Hope Parg inhibitors and method of use thereof
MX2021005154A (es) 2018-11-02 2021-07-15 Merck Sharp & Dohme Llc 2- amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8.
WO2020209932A1 (en) * 2019-04-12 2020-10-15 University Of Puerto Rico Compounds with antimalarial activity
CN111925357B (zh) * 2019-05-13 2023-06-06 中国科学院昆明植物研究所 一种酰腙类化合物及其药物组合物和其应用
WO2020261114A1 (en) 2019-06-27 2020-12-30 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroquinazolin compounds as nav1.8 inhibitors

Also Published As

Publication number Publication date
CA3227736A1 (en) 2023-02-09
WO2023010192A1 (pt) 2023-02-09
IL310571A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
PE20181045A1 (es) Compuestos utiles como inmunomoduladores
CO2021007056A2 (es) Nuevos compuestos heterocíclicos
PE20180573A1 (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR123424A1 (es) Nuevos compuestos heterocíclicos
AR107616A1 (es) Compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
EA201591614A1 (ru) Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения
AR083169A1 (es) Compuestos para tratar enfermedades neurodegenerativas
PE20200342A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CO6180438A2 (es) Compuestos que modulan actividad c-fms y/o c-kit y usos para ello
UY28157A1 (es) Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos
CO2020009567A2 (es) Inhibidores de monoacilglicerol lipasa (magl) de oxazina
CL2022000923A1 (es) Heterociclos bicíclicos como inhibidores de fgfr.
PA8634101A1 (es) DERIVADOS DE TETRAAZABENZO[e] AZULENO Y SUS ANALOGOS
GT200700036A (es) Compuestos fenil amido heterociclicos condensados
ECSP088738A (es) Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias
CL2020001930A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
CO2023014721A2 (es) Compuestos heterocíclicos
AR102731A1 (es) Compuestos espiroisoquinolin-1,4-piperidínicos con actividad multimodal contra el dolor
CL2021000171A1 (es) Procedimiento y productos intermedios para la preparación de bilastina
CO2022012476A2 (es) Hidrato cristalino de un compuesto inhibidor de jak
CO2022015893A2 (es) Compuestos y métodos dirigidos a interleucina-3
AR126670A1 (es) COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
CL2022003055A1 (es) Antagonistas del receptor de adenosina a2a
AR034585A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos